285 related articles for article (PubMed ID: 26770990)
1. Modulation Effect of Peroxisome Proliferator-Activated Receptor Agonists on Lipid Droplet Proteins in Liver.
Zhu YX; Zhang ML; Zhong Y; Wang C; Jia WP
J Diabetes Res; 2016; 2016():8315454. PubMed ID: 26770990
[TBL] [Abstract][Full Text] [Related]
2. Fenofibrate insulates diacylglycerol in lipid droplet/ER and preserves insulin signaling transduction in the liver of high fat fed mice.
Chan SM; Zeng XY; Sun RQ; Jo E; Zhou X; Wang H; Li S; Xu A; Watt MJ; Ye JM
Biochim Biophys Acta; 2015 Jul; 1852(7):1511-9. PubMed ID: 25906681
[TBL] [Abstract][Full Text] [Related]
3. Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages
Lefere S; Puengel T; Hundertmark J; Penners C; Frank AK; Guillot A; de Muynck K; Heymann F; Adarbes V; Defrêne E; Estivalet C; Geerts A; Devisscher L; Wettstein G; Tacke F
J Hepatol; 2020 Oct; 73(4):757-770. PubMed ID: 32360434
[TBL] [Abstract][Full Text] [Related]
4. Antidiabetic and hypolipidemic effects of a novel dual peroxisome proliferator-activated receptor (PPAR) alpha/gamma agonist, E3030, in db/db mice and beagle dogs.
Kasai S; Inoue T; Yoshitomi H; Hihara T; Matsuura F; Harada H; Shinoda M; Tanaka I
J Pharmacol Sci; 2008 Sep; 108(1):40-8. PubMed ID: 18776709
[TBL] [Abstract][Full Text] [Related]
5. Hepatic steatosis with relation to increased expression of peroxisome proliferator-activated receptor-γ in insulin resistant mice.
Satoh H; Ide N; Kagawa Y; Maeda T
Biol Pharm Bull; 2013; 36(4):616-23. PubMed ID: 23386130
[TBL] [Abstract][Full Text] [Related]
6. CIDEC/FSP27 is regulated by peroxisome proliferator-activated receptor alpha and plays a critical role in fasting- and diet-induced hepatosteatosis.
Langhi C; Baldán Á
Hepatology; 2015 Apr; 61(4):1227-38. PubMed ID: 25418138
[TBL] [Abstract][Full Text] [Related]
7. Peroxisome proliferator-activated receptor α activation induces hepatic steatosis, suggesting an adverse effect.
Yan F; Wang Q; Xu C; Cao M; Zhou X; Wang T; Yu C; Jing F; Chen W; Gao L; Zhao J
PLoS One; 2014; 9(6):e99245. PubMed ID: 24926685
[TBL] [Abstract][Full Text] [Related]
8. PPAR agonist-induced reduction of Mcp1 in atherosclerotic plaques of obese, insulin-resistant mice depends on adiponectin-induced Irak3 expression.
Hulsmans M; Geeraert B; Arnould T; Tsatsanis C; Holvoet P
PLoS One; 2013; 8(4):e62253. PubMed ID: 23620818
[TBL] [Abstract][Full Text] [Related]
9. Effects of PPARs agonists on cardiac metabolism in littermate and cardiomyocyte-specific PPAR-γ-knockout (CM-PGKO) mice.
Barbieri M; Di Filippo C; Esposito A; Marfella R; Rizzo MR; D'Amico M; Ferraraccio F; Di Ronza C; Duan SZ; Mortensen RM; Rossi F; Paolisso G
PLoS One; 2012; 7(4):e35999. PubMed ID: 22563432
[TBL] [Abstract][Full Text] [Related]
10. Rosiglitazone and fenofibrate exacerbate liver steatosis in a mouse model of obesity and hyperlipidemia. A transcriptomic and metabolomic study.
Rull A; Geeraert B; Aragonès G; Beltrán-Debón R; Rodríguez-Gallego E; García-Heredia A; Pedro-Botet J; Joven J; Holvoet P; Camps J
J Proteome Res; 2014 Mar; 13(3):1731-43. PubMed ID: 24479691
[TBL] [Abstract][Full Text] [Related]
11. Effects of cevoglitazar, a dual PPARalpha/gamma agonist, on ectopic fat deposition in fatty Zucker rats.
Laurent D; Gounarides JS; Gao J; Boettcher BR
Diabetes Obes Metab; 2009 Jun; 11(6):632-6. PubMed ID: 19175377
[TBL] [Abstract][Full Text] [Related]
12. Effect of Chronic Pioglitazone Treatment on Hepatic Gene Expression Profile in Obese C57BL/6J Mice.
Jia C; Huan Y; Liu S; Hou S; Sun S; Li C; Liu Q; Jiang Q; Wang Y; Shen Z
Int J Mol Sci; 2015 May; 16(6):12213-29. PubMed ID: 26035752
[TBL] [Abstract][Full Text] [Related]
13. Kaempferol regulates the lipid-profile in high-fat diet-fed rats through an increase in hepatic PPARα levels.
Chang CJ; Tzeng TF; Liou SS; Chang YS; Liu IM
Planta Med; 2011 Nov; 77(17):1876-82. PubMed ID: 21728151
[TBL] [Abstract][Full Text] [Related]
14.
Herrera-Marcos LV; Sancho-Knapik S; Gabás-Rivera C; Barranquero C; Gascón S; Romanos E; Martínez-Beamonte R; Navarro MA; Surra JC; Arnal C; García-de-Jalón JA; Rodríguez-Yoldi MJ; Tena-Sempere M; Sánchez-Ramos C; Monsalve M; Osada J
Am J Physiol Endocrinol Metab; 2020 Feb; 318(2):E249-E261. PubMed ID: 31846369
[TBL] [Abstract][Full Text] [Related]
15. Amelioration of diet-induced steatohepatitis in mice following combined therapy with ASO-Fsp27 and fenofibrate.
Rajamoorthi A; Arias N; Basta J; Lee RG; Baldán Á
J Lipid Res; 2017 Nov; 58(11):2127-2138. PubMed ID: 28874443
[TBL] [Abstract][Full Text] [Related]
16. Eburicoic Acid, a Triterpenoid Compound from Antrodia camphorata, Displays Antidiabetic and Antihyperlipidemic Effects in Palmitate-Treated C2C12 Myotubes and in High-Fat Diet-Fed Mice.
Lin CH; Kuo YH; Shih CC
Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29099085
[TBL] [Abstract][Full Text] [Related]
17. Osthole ameliorates insulin resistance by increment of adiponectin release in high-fat and high-sucrose-induced fatty liver rats.
Qi Z; Xue J; Zhang Y; Wang H; Xie M
Planta Med; 2011 Feb; 77(3):231-5. PubMed ID: 20717873
[TBL] [Abstract][Full Text] [Related]
18. Peroxisome proliferator-activated receptor-alpha gene level differently affects lipid metabolism and inflammation in apolipoprotein E2 knock-in mice.
Lalloyer F; Wouters K; Baron M; Caron S; Vallez E; Vanhoutte J; Baugé E; Shiri-Sverdlov R; Hofker M; Staels B; Tailleux A
Arterioscler Thromb Vasc Biol; 2011 Jul; 31(7):1573-9. PubMed ID: 21474829
[TBL] [Abstract][Full Text] [Related]
19. Fenretinide ameliorates insulin resistance and fatty liver in obese mice.
Koh IU; Jun HS; Choi JS; Lim JH; Kim WH; Yoon JB; Song J
Biol Pharm Bull; 2012; 35(3):369-75. PubMed ID: 22382323
[TBL] [Abstract][Full Text] [Related]
20. Liver Perilipin 5 Expression Worsens Hepatosteatosis But Not Insulin Resistance in High Fat-Fed Mice.
Trevino MB; Mazur-Hart D; Machida Y; King T; Nadler J; Galkina EV; Poddar A; Dutta S; Imai Y
Mol Endocrinol; 2015 Oct; 29(10):1414-25. PubMed ID: 26296152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
